ArticleBioactive materials2025
Inhibition of neuronal necroptosis via disruption of RIPK1-RIPK3 Interactions: The role of neural stem cell-derived exosomes in spinal cord injury recovery.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mitochondrial homeostasis imbalance-triggered PANoptosis in traumatic brain and spinal cord injury: from mechanism to therapeutic strategies.Redox biology · 2026Review
- Dynamic activation of lytic cell death-related programs identifies CD14 as a candidate hub gene associated with secondary injury after spinal cord injury.Frontiers in immunology · 2026Article
- Emerging strategies for spinal cord injury repair: stem cells, extracellular vesicles, biomaterials, and neuromodulation.Frontiers in bioengineering and biotechnology · 2026Review
- PANoptosis: a new perspective for targeting programmed cell death after spinal cord injury.Frontiers in immunology · 2026Review
- Exosomes as regenerative therapeutics for spinal cord injury: mechanisms and clinical prospects.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) poses a significant economic and public health burden. Exosomes derived from neural stem cells (NSC-Exos) are emerging as a promising therapeutic strategy for SCI repair, overcoming several limitations associated with both autologous and allogeneic neural stem cell therapies. This study demonstrates that NSC-Exos are efficiently internalized by the injured spinal cord after co-injection, resulting in substantial motor function recovery in murine models. Additionally, NSC-Exos effectively limit the expansion of the injury site, reduce neuronal degeneration, and attenuate neuroinflammatory responses. Notably, this is the first study to identify necroptosis as a novel therapeutic target for NSC-Exos in SCI recovery. We show that NSC-Exos inhibit neuronal necroptosis both in vivo and in vitro by disrupting the RIPK1-RIPK3 interaction, thereby preventing necrosome assembly. Furthermore, comprehensive transcriptomic analysis reveals that the ubiquitin-mediated proteolysis (UPS) pathway plays a crucial role in this process, a finding supported by experimental inhibition of ubiquitination. In conclusion, this study highlights the therapeutic potential of NSC-Exos in SCI treatment, particularly through the inhibition of necroptosis via disruption of the RIPK1-RIPK3 interaction, potentially involving UPS activation. These findings provide a foundation for future investigations into the molecular mechanisms underlying SCI recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.